Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma	classic Hodgkin lymphoma	Active, not recruiting	Phase 2	2026-09-24		NCT02940301

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Ohio State University Comprehensive Cancer Center	112

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Ohio State University Comprehensive Cancer Center	Columbus	United States	548
Winship Cancer Center of Emory University	Atlanta	United States	1

Clinical trials